IBDEI174 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,19212,2)
 ;;=^5133578
 ;;^UTILITY(U,$J,358.3,19213,0)
 ;;=I69.241^^93^989^69
 ;;^UTILITY(U,$J,358.3,19213,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19213,1,3,0)
 ;;=3^Monoplg low lmb fol oth ntrm intcrn hemor aff right dom side
 ;;^UTILITY(U,$J,358.3,19213,1,4,0)
 ;;=4^I69.241
 ;;^UTILITY(U,$J,358.3,19213,2)
 ;;=^5007469
 ;;^UTILITY(U,$J,358.3,19214,0)
 ;;=I69.242^^93^989^70
 ;;^UTILITY(U,$J,358.3,19214,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19214,1,3,0)
 ;;=3^Monoplg low lmb fol oth ntrm intcrn hemor aff left dom side
 ;;^UTILITY(U,$J,358.3,19214,1,4,0)
 ;;=4^I69.242
 ;;^UTILITY(U,$J,358.3,19214,2)
 ;;=^5133574
 ;;^UTILITY(U,$J,358.3,19215,0)
 ;;=I69.243^^93^989^71
 ;;^UTILITY(U,$J,358.3,19215,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19215,1,3,0)
 ;;=3^Monoplg low lmb fol oth ntrm intcrn hemor aff r nondom side
 ;;^UTILITY(U,$J,358.3,19215,1,4,0)
 ;;=4^I69.243
 ;;^UTILITY(U,$J,358.3,19215,2)
 ;;=^5007470
 ;;^UTILITY(U,$J,358.3,19216,0)
 ;;=I69.244^^93^989^72
 ;;^UTILITY(U,$J,358.3,19216,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19216,1,3,0)
 ;;=3^Monoplg low lmb fol oth ntrm intcrn hemor aff l nondom side
 ;;^UTILITY(U,$J,358.3,19216,1,4,0)
 ;;=4^I69.244
 ;;^UTILITY(U,$J,358.3,19216,2)
 ;;=^5007471
 ;;^UTILITY(U,$J,358.3,19217,0)
 ;;=G35.^^93^989^73
 ;;^UTILITY(U,$J,358.3,19217,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19217,1,3,0)
 ;;=3^Multiple sclerosis
 ;;^UTILITY(U,$J,358.3,19217,1,4,0)
 ;;=4^G35.
 ;;^UTILITY(U,$J,358.3,19217,2)
 ;;=^79761
 ;;^UTILITY(U,$J,358.3,19218,0)
 ;;=G20.^^93^989^74
 ;;^UTILITY(U,$J,358.3,19218,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19218,1,3,0)
 ;;=3^Parkinson's disease
 ;;^UTILITY(U,$J,358.3,19218,1,4,0)
 ;;=4^G20.
 ;;^UTILITY(U,$J,358.3,19218,2)
 ;;=^5003770
 ;;^UTILITY(U,$J,358.3,19219,0)
 ;;=G21.4^^93^989^75
 ;;^UTILITY(U,$J,358.3,19219,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19219,1,3,0)
 ;;=3^Vascular parkinsonism
 ;;^UTILITY(U,$J,358.3,19219,1,4,0)
 ;;=4^G21.4
 ;;^UTILITY(U,$J,358.3,19219,2)
 ;;=^5003776
 ;;^UTILITY(U,$J,358.3,19220,0)
 ;;=I69.051^^93^989^43
 ;;^UTILITY(U,$J,358.3,19220,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19220,1,3,0)
 ;;=3^Hemiplga fol ntrm subarach hemor aff right dominant side
 ;;^UTILITY(U,$J,358.3,19220,1,4,0)
 ;;=4^I69.051
 ;;^UTILITY(U,$J,358.3,19220,2)
 ;;=^5007409
 ;;^UTILITY(U,$J,358.3,19221,0)
 ;;=I69.052^^93^989^41
 ;;^UTILITY(U,$J,358.3,19221,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19221,1,3,0)
 ;;=3^Hemiplga fol ntrm subarach hemor aff left dominant side
 ;;^UTILITY(U,$J,358.3,19221,1,4,0)
 ;;=4^I69.052
 ;;^UTILITY(U,$J,358.3,19221,2)
 ;;=^5007410
 ;;^UTILITY(U,$J,358.3,19222,0)
 ;;=I69.053^^93^989^44
 ;;^UTILITY(U,$J,358.3,19222,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19222,1,3,0)
 ;;=3^Hemiplga fol ntrm subarach hemor aff right nondom side
 ;;^UTILITY(U,$J,358.3,19222,1,4,0)
 ;;=4^I69.053
 ;;^UTILITY(U,$J,358.3,19222,2)
 ;;=^5007411
 ;;^UTILITY(U,$J,358.3,19223,0)
 ;;=I69.054^^93^989^42
 ;;^UTILITY(U,$J,358.3,19223,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19223,1,3,0)
 ;;=3^Hemiplga fol ntrm subarach hemor aff left nondom side
 ;;^UTILITY(U,$J,358.3,19223,1,4,0)
 ;;=4^I69.054
 ;;^UTILITY(U,$J,358.3,19223,2)
 ;;=^5007412
 ;;^UTILITY(U,$J,358.3,19224,0)
 ;;=I50.41^^93^990^1
 ;;^UTILITY(U,$J,358.3,19224,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19224,1,3,0)
 ;;=3^Acute combined systolic and diastolic (congestive) hrt fail
